Total Payments
$3,148
2024 Payments
$2,001
Companies
17
Transactions
134
Medicare Patients
3,303
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$3,094 (98.3%)
Education$54.56 (1.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,094 | 131 | 98.3% |
| Education | $54.56 | 3 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,066 | 45 | $0 (2024) |
| Janssen Biotech, Inc. | $395.29 | 23 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $329.91 | 11 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $299.10 | 14 | $0 (2024) |
| PFIZER INC. | $282.36 | 11 | $0 (2024) |
| Gilead Sciences, Inc. | $164.31 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $132.18 | 2 | $0 (2022) |
| GENZYME CORPORATION | $99.07 | 3 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $56.89 | 3 | $0 (2024) |
| Lilly USA, LLC | $55.34 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,001 | 95 | ABBVIE INC. ($556.34) |
| 2023 | $311.60 | 11 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($166.39) |
| 2022 | $634.54 | 17 | ABBVIE INC. ($460.76) |
| 2021 | $201.00 | 11 | Gilead Sciences, Inc. ($134.08) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $26.68 | General |
| Category: Gastroenterology | ||||||
| 12/10/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.23 | General |
| 12/05/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Immunology | ||||||
| 11/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $41.27 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: Immunology | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $8.49 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/24/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $26.83 | General |
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: Immunology | ||||||
| 10/22/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: Immunology | ||||||
| 10/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $34.68 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/14/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/07/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $6.42 | General |
| Category: IMMUNOLOGY | ||||||
| 10/05/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 585 | 23,816 | $1.6M | $481,163 |
| 2022 | 23 | 910 | 20,978 | $1.3M | $432,050 |
| 2021 | 21 | 872 | 35,019 | $1.9M | $621,687 |
| 2020 | 21 | 936 | 28,858 | $1.6M | $562,511 |
Total Patients
3,303
Total Services
108,671
Medicare Billing
$2.1M
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 20 | 18,000 | $774,000 | $308,046 | 39.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 24 | 4,810 | $625,300 | $125,075 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 115 | 148 | $46,032 | $10,855 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 156 | $33,009 | $8,326 | 25.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 20 | 231 | $25,641 | $7,281 | 28.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 27 | 64 | $27,860 | $5,622 | 20.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 21 | 133 | $21,280 | $5,458 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $15,726 | $3,171 | 20.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 62 | $13,390 | $2,700 | 20.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 45 | 45 | $12,555 | $2,598 | 20.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 31 | $5,642 | $1,071 | 19.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 31 | 35 | $350.00 | $294.00 | 84.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 24 | 27 | $729.00 | $279.45 | 38.3% |
| 82105 | Alpha-fetoprotein (afp) level, serum | Office | 2023 | 12 | 12 | $636.00 | $197.16 | 31.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 23 | 25 | $625.00 | $190.25 | 30.4% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 22 | 14,703 | $632,100 | $241,746 | 38.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 21 | 4,770 | $362,520 | $132,820 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 175 | 223 | $88,085 | $16,075 | 18.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 27 | 272 | $38,624 | $8,740 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 133 | 148 | $41,440 | $7,397 | 17.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 25 | 69 | $30,291 | $6,358 | 21.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 28 | 149 | $27,863 | $6,325 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $19,305 | $3,281 | 17.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 25 | 57 | $12,312 | $2,489 | 20.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $6,900 | $1,315 | 19.1% |
About Michelle Hendrickx, ARNP
Michelle Hendrickx, ARNP is a Family healthcare provider based in Tacoma, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346213014.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michelle Hendrickx, ARNP has received a total of $3,148 in payments from pharmaceutical and medical device companies, with $2,001 received in 2024. These payments were reported across 134 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($3,094).
As a Medicare-enrolled provider, Hendrickx has provided services to 3,303 Medicare beneficiaries, totaling 108,671 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Tacoma, WA
- Active Since 02/10/2006
- Last Updated 10/17/2017
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1346213014
Products in Payments
- XIFAXAN (Drug) $329.91
- CREON (Drug) $317.90
- XELJANZ (Drug) $282.36
- STELARA (Biological) $275.44
- ENTYVIO (Biological) $270.37
- RINVOQ (Biological) $224.52
- SKYRIZI (Biological) $184.82
- ZEPOSIA (Drug) $153.04
- MAVYRET (Drug) $128.17
- DUPIXENT (Biological) $127.90
- LINZESS (Drug) $126.61
- TREMFYA (Drug) $119.85
- Epclusa (Drug) $100.00
- VOQUEZNA (Drug) $56.89
- OMVOH (Drug) $55.34
- INJECTAFER (Drug) $49.22
- ZYMFENTRA (Biological) $45.47
- VIBERZI (Drug) $41.22
- IBSRELA (Drug) $41.19
- HADLIMA (Drug) $40.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Tacoma
Ms. Loan Retchless, Np, NP
Family — Payments: $20,172
Family $20,172
Tammi Hudspeth, Arnp, ARNP
Family — Payments: $7,089
Family $7,089
Mrs. Nasla Loya, Fnp, FNP
Family — Payments: $5,249
Family $5,249
Simon Katumu, Np, NP
Family — Payments: $4,389
Family $4,389
Miss. Marina Cawthra, Aprn, APRN
Family — Payments: $2,705
Family $2,705
Whitney Eng, Arnp, ARNP
Family — Payments: $2,492
Family $2,492